Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives
TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. However, Grave's disease is a kind of systemic autoimmune syndrome which might involve the thyroid, the e...
Uloženo v:
| Vydáno v: | Current eye research Ročník 45; číslo 11; s. 1325 - 1341 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Taylor & Francis
01.11.2020
|
| Témata: | |
| ISSN: | 0271-3683, 1460-2202, 1460-2202 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. However, Grave's disease is a kind of systemic autoimmune syndrome which might involve the thyroid, the eye ball and the anterior tibial tissue. Considering the inexplicable understanding of TAO pathogenesis, the disease worsens for the patients. Therefore, this manuscript provides insights into the recent advancements of clinical features, epidemiology, pathogenesis with gene-interactions, diagnosis, including available and novel treatment options for TAO, based on available data including RCTs, meta-analyses, and systematic reviews.
Articles with clinical features, epidemiology, pathogenesis, diagnosis, and treatment of the disease were thoroughly studied. To perform the gene expression and pathway analysis, articles were searched on PubMed, MEDLINE Cochrane Library and ClinicalTrial.gov from 1982 to 2020. To predict novel TAO-specific therapeutic molecule, structure-based drug design (SBDD) was performed.
We observed gene expression and pathway analysis and SBDD approaches might bring new insights in the field of TAO pathogenesis, diagnosis, and treatment. A genome-wide map of human genetic interactions revealed involvement of crucial cell-signalling pathways, such as TNF-mediated signalling pathway, type-I interferon signalling pathway, toll-like receptor signalling pathway, transforming growth factor-beta receptor signalling pathway etc. Recently, FDA-approved teprotumumab a breakthrough, first drug for the treatment of active thyroid eye disease, which reduces proptosis and the need for orbital decompression surgery. Furthermore, our SBDD results revealed that cost-effective Curcumin, Withaferin A, Resveratrol, Scopolamine, Quercetin, and Berberine may have significant binding affinity for hyaluronan protein and may be exploited for therapeutic purposes in TAO.
Considering the increasing risk and nature of disease, novel drug therapies and markers for prognosis need to be investigated. Moreover, evidence-based non-invasive/minimal surgical therapies should be developed for the better management of the disease.
ADIPOQ: Adiponectin; CAS: Clinical Activity Score; CCL5: C-C Motif Chemokine Ligand 5; CT: Computed Tomography; DON: Dysthyroid Optic Neuropathy; EUGOGO: European Group of Graves' Orbitopathy; FDA: U.S. Food and Drug Administration; FOS: Fos Proto-Oncogene, AP-1 Transcription Factor Subunit; HLA: Human Leukocyte Antigen; HLA-DRA: Major Histocompatibility Complex, Class II, DR Alpha; ICAM1: Intercellular Adhesion Molecule 1; IFNG: Interferon Gamma; IGF-1: Insulin-like Growth Factor 1; IGF-1R: Insulin-like Growth Factor-1 Receptor; IL12B: Interleukin 12B; IL23R: Interleukin 23 Receptor; IL6: Interleukin 6; IOP: Intraocular Pressure; IRF1: Interferon Regulatory Factor 1; IRF5: Interferon Regulatory Factor 5; IRF7: Interferon Regulatory Factor 7; IRF9: Interferon Regulatory Factor 9; JUN: Jun Proto-Oncogene, AP-1 Transcription Factor Subunit; JUNB: JunB Proto-Oncogene, AP-1 Transcription Factor Subunit; MHC: Major Histocompatibility Complex; MRI: Magnetic Resonance Imaging; NFKB1: Nuclear Factor Kappa B Subunit 1; NFKBIA: Nuclear Factor Kappa B Inhibitor Alpha; OADSCs: Orbital Adipose Derived Stromal Cells; PDGFB: Platelet Derived Growth Factor Subunit B; PPARG: Peroxisome Proliferator Activated Receptor Gamma; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; RARA: Retinoic Acid Receptor Alpha; RCTs (Randomized Controlled Trials; SLE: Systemic lupus erythematosus; SOCS3: Suppressor of Cytokine Signaling 3; STAT1: Signal Transducer and Activator of Transcription 1; TAO: Thyroid-Associated Ophthalmopathy; TED: Thyroid eye disease; TGFB1: Transforming Growth Factor Beta 1; TGFB2: Transforming Growth Factor Beta 2; TGF-β: Transforming Growth Factor-beta; TLR7: Toll like Receptor 7; TLR9: Toll like Receptor 9; TNFRSF18: Tumor Necrosis Factor Receptor Superfamily Member 18; TNFSF11: Tumor Necrosis Factor Receptor Superfamily Member 11; TNF-α: Tumor Necrosis Factor-alpha; TSHR: Thyroid Stimulating Hormone Receptor; TSIs: Thyroid Stimulating Immunoglobulin; WNT5A: Wingless-Type MMTV Integration Site Family, Member 5A. |
|---|---|
| AbstractList | TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. However, Grave's disease is a kind of systemic autoimmune syndrome which might involve the thyroid, the eye ball and the anterior tibial tissue. Considering the inexplicable understanding of TAO pathogenesis, the disease worsens for the patients. Therefore, this manuscript provides insights into the recent advancements of clinical features, epidemiology, pathogenesis with gene-interactions, diagnosis, including available and novel treatment options for TAO, based on available data including RCTs, meta-analyses, and systematic reviews.
Articles with clinical features, epidemiology, pathogenesis, diagnosis, and treatment of the disease were thoroughly studied. To perform the gene expression and pathway analysis, articles were searched on PubMed, MEDLINE Cochrane Library and ClinicalTrial.gov from 1982 to 2020. To predict novel TAO-specific therapeutic molecule, structure-based drug design (SBDD) was performed.
We observed gene expression and pathway analysis and SBDD approaches might bring new insights in the field of TAO pathogenesis, diagnosis, and treatment. A genome-wide map of human genetic interactions revealed involvement of crucial cell-signalling pathways, such as TNF-mediated signalling pathway, type-I interferon signalling pathway, toll-like receptor signalling pathway, transforming growth factor-beta receptor signalling pathway etc. Recently, FDA-approved teprotumumab a breakthrough, first drug for the treatment of active thyroid eye disease, which reduces proptosis and the need for orbital decompression surgery. Furthermore, our SBDD results revealed that cost-effective Curcumin, Withaferin A, Resveratrol, Scopolamine, Quercetin, and Berberine may have significant binding affinity for hyaluronan protein and may be exploited for therapeutic purposes in TAO.
Considering the increasing risk and nature of disease, novel drug therapies and markers for prognosis need to be investigated. Moreover, evidence-based non-invasive/minimal surgical therapies should be developed for the better management of the disease.
ADIPOQ: Adiponectin; CAS: Clinical Activity Score; CCL5: C-C Motif Chemokine Ligand 5; CT: Computed Tomography; DON: Dysthyroid Optic Neuropathy; EUGOGO: European Group of Graves' Orbitopathy; FDA: U.S. Food and Drug Administration; FOS: Fos Proto-Oncogene, AP-1 Transcription Factor Subunit; HLA: Human Leukocyte Antigen; HLA-DRA: Major Histocompatibility Complex, Class II, DR Alpha; ICAM1: Intercellular Adhesion Molecule 1; IFNG: Interferon Gamma; IGF-1: Insulin-like Growth Factor 1; IGF-1R: Insulin-like Growth Factor-1 Receptor; IL12B: Interleukin 12B; IL23R: Interleukin 23 Receptor; IL6: Interleukin 6; IOP: Intraocular Pressure; IRF1: Interferon Regulatory Factor 1; IRF5: Interferon Regulatory Factor 5; IRF7: Interferon Regulatory Factor 7; IRF9: Interferon Regulatory Factor 9; JUN: Jun Proto-Oncogene, AP-1 Transcription Factor Subunit; JUNB: JunB Proto-Oncogene, AP-1 Transcription Factor Subunit; MHC: Major Histocompatibility Complex; MRI: Magnetic Resonance Imaging; NFKB1: Nuclear Factor Kappa B Subunit 1; NFKBIA: Nuclear Factor Kappa B Inhibitor Alpha; OADSCs: Orbital Adipose Derived Stromal Cells; PDGFB: Platelet Derived Growth Factor Subunit B; PPARG: Peroxisome Proliferator Activated Receptor Gamma; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; RARA: Retinoic Acid Receptor Alpha; RCTs (Randomized Controlled Trials; SLE: Systemic lupus erythematosus; SOCS3: Suppressor of Cytokine Signaling 3; STAT1: Signal Transducer and Activator of Transcription 1; TAO: Thyroid-Associated Ophthalmopathy; TED: Thyroid eye disease; TGFB1: Transforming Growth Factor Beta 1; TGFB2: Transforming Growth Factor Beta 2; TGF-β: Transforming Growth Factor-beta; TLR7: Toll like Receptor 7; TLR9: Toll like Receptor 9; TNFRSF18: Tumor Necrosis Factor Receptor Superfamily Member 18; TNFSF11: Tumor Necrosis Factor Receptor Superfamily Member 11; TNF-α: Tumor Necrosis Factor-alpha; TSHR: Thyroid Stimulating Hormone Receptor; TSIs: Thyroid Stimulating Immunoglobulin; WNT5A: Wingless-Type MMTV Integration Site Family, Member 5A. TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. However, Grave's disease is a kind of systemic autoimmune syndrome which might involve the thyroid, the eye ball and the anterior tibial tissue. Considering the inexplicable understanding of TAO pathogenesis, the disease worsens for the patients. Therefore, this manuscript provides insights into the recent advancements of clinical features, epidemiology, pathogenesis with gene-interactions, diagnosis, including available and novel treatment options for TAO, based on available data including RCTs, meta-analyses, and systematic reviews.PURPOSETAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. However, Grave's disease is a kind of systemic autoimmune syndrome which might involve the thyroid, the eye ball and the anterior tibial tissue. Considering the inexplicable understanding of TAO pathogenesis, the disease worsens for the patients. Therefore, this manuscript provides insights into the recent advancements of clinical features, epidemiology, pathogenesis with gene-interactions, diagnosis, including available and novel treatment options for TAO, based on available data including RCTs, meta-analyses, and systematic reviews.Articles with clinical features, epidemiology, pathogenesis, diagnosis, and treatment of the disease were thoroughly studied. To perform the gene expression and pathway analysis, articles were searched on PubMed, MEDLINE Cochrane Library and ClinicalTrial.gov from 1982 to 2020. To predict novel TAO-specific therapeutic molecule, structure-based drug design (SBDD) was performed.METHODSArticles with clinical features, epidemiology, pathogenesis, diagnosis, and treatment of the disease were thoroughly studied. To perform the gene expression and pathway analysis, articles were searched on PubMed, MEDLINE Cochrane Library and ClinicalTrial.gov from 1982 to 2020. To predict novel TAO-specific therapeutic molecule, structure-based drug design (SBDD) was performed.We observed gene expression and pathway analysis and SBDD approaches might bring new insights in the field of TAO pathogenesis, diagnosis, and treatment. A genome-wide map of human genetic interactions revealed involvement of crucial cell-signalling pathways, such as TNF-mediated signalling pathway, type-I interferon signalling pathway, toll-like receptor signalling pathway, transforming growth factor-beta receptor signalling pathway etc. Recently, FDA-approved teprotumumab a breakthrough, first drug for the treatment of active thyroid eye disease, which reduces proptosis and the need for orbital decompression surgery. Furthermore, our SBDD results revealed that cost-effective Curcumin, Withaferin A, Resveratrol, Scopolamine, Quercetin, and Berberine may have significant binding affinity for hyaluronan protein and may be exploited for therapeutic purposes in TAO.RESULTSWe observed gene expression and pathway analysis and SBDD approaches might bring new insights in the field of TAO pathogenesis, diagnosis, and treatment. A genome-wide map of human genetic interactions revealed involvement of crucial cell-signalling pathways, such as TNF-mediated signalling pathway, type-I interferon signalling pathway, toll-like receptor signalling pathway, transforming growth factor-beta receptor signalling pathway etc. Recently, FDA-approved teprotumumab a breakthrough, first drug for the treatment of active thyroid eye disease, which reduces proptosis and the need for orbital decompression surgery. Furthermore, our SBDD results revealed that cost-effective Curcumin, Withaferin A, Resveratrol, Scopolamine, Quercetin, and Berberine may have significant binding affinity for hyaluronan protein and may be exploited for therapeutic purposes in TAO.Considering the increasing risk and nature of disease, novel drug therapies and markers for prognosis need to be investigated. Moreover, evidence-based non-invasive/minimal surgical therapies should be developed for the better management of the disease.CONCLUSIONSConsidering the increasing risk and nature of disease, novel drug therapies and markers for prognosis need to be investigated. Moreover, evidence-based non-invasive/minimal surgical therapies should be developed for the better management of the disease.ADIPOQ: Adiponectin; CAS: Clinical Activity Score; CCL5: C-C Motif Chemokine Ligand 5; CT: Computed Tomography; DON: Dysthyroid Optic Neuropathy; EUGOGO: European Group of Graves' Orbitopathy; FDA: U.S. Food and Drug Administration; FOS: Fos Proto-Oncogene, AP-1 Transcription Factor Subunit; HLA: Human Leukocyte Antigen; HLA-DRA: Major Histocompatibility Complex, Class II, DR Alpha; ICAM1: Intercellular Adhesion Molecule 1; IFNG: Interferon Gamma; IGF-1: Insulin-like Growth Factor 1; IGF-1R: Insulin-like Growth Factor-1 Receptor; IL12B: Interleukin 12B; IL23R: Interleukin 23 Receptor; IL6: Interleukin 6; IOP: Intraocular Pressure; IRF1: Interferon Regulatory Factor 1; IRF5: Interferon Regulatory Factor 5; IRF7: Interferon Regulatory Factor 7; IRF9: Interferon Regulatory Factor 9; JUN: Jun Proto-Oncogene, AP-1 Transcription Factor Subunit; JUNB: JunB Proto-Oncogene, AP-1 Transcription Factor Subunit; MHC: Major Histocompatibility Complex; MRI: Magnetic Resonance Imaging; NFKB1: Nuclear Factor Kappa B Subunit 1; NFKBIA: Nuclear Factor Kappa B Inhibitor Alpha; OADSCs: Orbital Adipose Derived Stromal Cells; PDGFB: Platelet Derived Growth Factor Subunit B; PPARG: Peroxisome Proliferator Activated Receptor Gamma; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; RARA: Retinoic Acid Receptor Alpha; RCTs (Randomized Controlled Trials; SLE: Systemic lupus erythematosus; SOCS3: Suppressor of Cytokine Signaling 3; STAT1: Signal Transducer and Activator of Transcription 1; TAO: Thyroid-Associated Ophthalmopathy; TED: Thyroid eye disease; TGFB1: Transforming Growth Factor Beta 1; TGFB2: Transforming Growth Factor Beta 2; TGF-β: Transforming Growth Factor-beta; TLR7: Toll like Receptor 7; TLR9: Toll like Receptor 9; TNFRSF18: Tumor Necrosis Factor Receptor Superfamily Member 18; TNFSF11: Tumor Necrosis Factor Receptor Superfamily Member 11; TNF-α: Tumor Necrosis Factor-alpha; TSHR: Thyroid Stimulating Hormone Receptor; TSIs: Thyroid Stimulating Immunoglobulin; WNT5A: Wingless-Type MMTV Integration Site Family, Member 5A.ABBREVIATIONSADIPOQ: Adiponectin; CAS: Clinical Activity Score; CCL5: C-C Motif Chemokine Ligand 5; CT: Computed Tomography; DON: Dysthyroid Optic Neuropathy; EUGOGO: European Group of Graves' Orbitopathy; FDA: U.S. Food and Drug Administration; FOS: Fos Proto-Oncogene, AP-1 Transcription Factor Subunit; HLA: Human Leukocyte Antigen; HLA-DRA: Major Histocompatibility Complex, Class II, DR Alpha; ICAM1: Intercellular Adhesion Molecule 1; IFNG: Interferon Gamma; IGF-1: Insulin-like Growth Factor 1; IGF-1R: Insulin-like Growth Factor-1 Receptor; IL12B: Interleukin 12B; IL23R: Interleukin 23 Receptor; IL6: Interleukin 6; IOP: Intraocular Pressure; IRF1: Interferon Regulatory Factor 1; IRF5: Interferon Regulatory Factor 5; IRF7: Interferon Regulatory Factor 7; IRF9: Interferon Regulatory Factor 9; JUN: Jun Proto-Oncogene, AP-1 Transcription Factor Subunit; JUNB: JunB Proto-Oncogene, AP-1 Transcription Factor Subunit; MHC: Major Histocompatibility Complex; MRI: Magnetic Resonance Imaging; NFKB1: Nuclear Factor Kappa B Subunit 1; NFKBIA: Nuclear Factor Kappa B Inhibitor Alpha; OADSCs: Orbital Adipose Derived Stromal Cells; PDGFB: Platelet Derived Growth Factor Subunit B; PPARG: Peroxisome Proliferator Activated Receptor Gamma; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; RARA: Retinoic Acid Receptor Alpha; RCTs (Randomized Controlled Trials; SLE: Systemic lupus erythematosus; SOCS3: Suppressor of Cytokine Signaling 3; STAT1: Signal Transducer and Activator of Transcription 1; TAO: Thyroid-Associated Ophthalmopathy; TED: Thyroid eye disease; TGFB1: Transforming Growth Factor Beta 1; TGFB2: Transforming Growth Factor Beta 2; TGF-β: Transforming Growth Factor-beta; TLR7: Toll like Receptor 7; TLR9: Toll like Receptor 9; TNFRSF18: Tumor Necrosis Factor Receptor Superfamily Member 18; TNFSF11: Tumor Necrosis Factor Receptor Superfamily Member 11; TNF-α: Tumor Necrosis Factor-alpha; TSHR: Thyroid Stimulating Hormone Receptor; TSIs: Thyroid Stimulating Immunoglobulin; WNT5A: Wingless-Type MMTV Integration Site Family, Member 5A. |
| Author | Kaur, Apjit Kumar, Swatantra Saxena, Shailendra K Mishra, Shailja Maurya, Vimal K |
| Author_xml | – sequence: 1 givenname: Shailja surname: Mishra fullname: Mishra, Shailja organization: King George's Medical University (KGMU) – sequence: 2 givenname: Vimal K surname: Maurya fullname: Maurya, Vimal K organization: King George's Medical University (KGMU) – sequence: 3 givenname: Swatantra surname: Kumar fullname: Kumar, Swatantra organization: King George's Medical University (KGMU) – sequence: 4 givenname: Ankita organization: King George's Medical University (KGMU) – sequence: 5 givenname: Apjit surname: Kaur fullname: Kaur, Apjit email: apjitkaur@kgmcindia.edu organization: King George's Medical University (KGMU) – sequence: 6 givenname: Shailendra K orcidid: 0000-0003-2856-4185 surname: Saxena fullname: Saxena, Shailendra K email: shailen@kgmcindia.edu organization: King George's Medical University (KGMU) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32567373$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUFv1DAUhC1URLeFnwDKkUuKHTuxFy5UKwpIRUWinK0X57lrlNjBdory70m0uxw4wOlJ876Zw8wFOfPBIyEvGb1iVNE3tJKMN4pfVbRaJCkbztkTsmGioWW1iGdkszLlCp2Ti5R-ULoK4hk551XdSC75hsy73nlnoC--gIcHHNDnAnxX3O8xwohTdqb4liNkfHCYChtikfe4vOcYXFdepxSMW75dcTfu8x76IYyQ9_PbYjfFeEq7mfIUsfiKMY1osnvE9Jw8tdAnfHG8l-T7zYf73afy9u7j5931bWmE4rlEpawx3XbbGjQSqZWsNtAobEEIbsEoaFhDK2u3WyVbLptWqAZbYWuugHF-SV4fcscYfk6Ysh5cMtj34DFMSVeC1YpLUYsFfXVEp3bATo_RDRBnfaprAeoDYGJIKaL9gzCq11n0aRa9zqKPsyy-d3_5jMuQXfBLs67_r_v9we38Uv8Av0LsO51h7kO0EbxxSfN_R_wGuOSntw |
| CitedBy_id | crossref_primary_10_1016_j_jbi_2024_104759 crossref_primary_10_1016_j_pdpdt_2025_104578 crossref_primary_10_1016_j_compbiomed_2025_110301 crossref_primary_10_1038_s41598_025_05107_9 crossref_primary_10_1016_j_envres_2023_116116 crossref_primary_10_3390_jpm14070776 crossref_primary_10_1007_s42000_021_00282_6 crossref_primary_10_1007_s13337_024_00900_y crossref_primary_10_1111_ene_16242 crossref_primary_10_1007_s10792_022_02621_x crossref_primary_10_1016_j_pdpdt_2023_103805 crossref_primary_10_3389_fendo_2024_1400869 crossref_primary_10_1080_01676830_2024_2414770 crossref_primary_10_1177_11206721211023725 crossref_primary_10_1007_s00330_025_11691_1 crossref_primary_10_1111_aos_15074 crossref_primary_10_1097_SCS_0000000000009919 crossref_primary_10_1016_j_bjoms_2022_11_284 crossref_primary_10_3389_fimmu_2024_1475923 crossref_primary_10_1016_j_ando_2025_101729 crossref_primary_10_1016_j_brainres_2022_147989 crossref_primary_10_3390_antib14030055 crossref_primary_10_1007_s11940_021_00675_3 crossref_primary_10_1097_IOP_0000000000002555 crossref_primary_10_3390_bioengineering11121181 crossref_primary_10_1186_s12886_023_02957_7 crossref_primary_10_3390_molecules28010015 crossref_primary_10_1530_EC_22_0303 crossref_primary_10_3389_fendo_2025_1527376 crossref_primary_10_3389_fmed_2022_936819 crossref_primary_10_17816_PAVLOVJ625993 crossref_primary_10_1515_biol_2022_0694 crossref_primary_10_1055_a_2007_2631 crossref_primary_10_1186_s13018_025_05557_x crossref_primary_10_1002_iid3_1304 crossref_primary_10_1186_s12902_025_01981_6 crossref_primary_10_1016_j_aopr_2023_11_002 crossref_primary_10_1136_bmjopen_2021_053173 crossref_primary_10_1016_j_heliyon_2024_e35589 |
| Cites_doi | 10.1016/j.ejro.2019.05.003 10.2147/OPTH.S205112 10.2174/1389201020666190725113816 10.1097/IOP.0000000000000260 10.1111/j.2517-6161.1995.tb02031.x 10.1167/iovs.13-12741 10.1016/S1097-2765(04)00080-2 10.1530/JOE-11-0162 10.1007/s40618-018-0915-z 10.1016/j.beem.2019.101319 10.1016/j.ajoc.2017.07.001 10.1136/bjophthalmol-2014-305649 10.2147/OPTH.S76583 10.1038/s41598-017-17257-6 10.1016/j.gene.2018.11.097 10.1186/s12886-018-0969-x 10.1016/j.beem.2011.10.004 10.2147/OPTH.S216838 10.2169/internalmedicine.53.1518 10.1038/sj.eye.6701768 10.1007/s11684-017-0528-5 10.1186/s12859-017-1559-2 10.1097/ICU.0000000000000596 10.1056/NEJMicm1506674 10.1007/s40618-014-0097-2 10.1038/s41433-018-0022-6 10.1007/s40265-018-1045-9 10.1259/bjr.20140677 10.1056/NEJMoa1910434 10.3389/fendo.2017.00137 10.1056/NEJMoa1614949 10.1038/s41598-017-17893-y 10.1146/annurev-pharmtox-010617-052509 10.1055/a-0739-8134 10.1016/j.survophthal.2017.03.007 10.1089/thy.2008.0044 10.1089/omi.2009.0045 10.22088/cjim.9.2.178 10.1016/j.jfma.2018.06.009 10.1136/bjophthalmol-2015-307399 10.1016/j.radcr.2019.04.021 10.1038/s41433-018-0279-9 10.12688/f1000research.12787.1 10.1007/978-1-4939-7531-0_2 10.1155/2015/249125 10.1186/s40842-016-0037-5 10.1136/bjo.73.8.639 10.1093/nar/gky311 10.1093/asj/sjy085 10.1586/17512433.2016.1165606 10.1038/s41433-018-0315-9 10.1210/jcem.81.8.8768861 10.1007/s00234-018-2103-4 10.1080/14728222.2017.1288215 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U 10.1016/S0002-9394(14)72666-2 10.1016/j.jamcollsurg.2009.03.025 10.15557/JoU.2015.0036 10.1097/IOP.0000000000001446 10.1167/iovs.14-14002 10.1186/s12886-018-1018-5 10.1038/srep42717 10.1530/JME-17-0276 10.1038/s41433-018-0265-2 10.1038/clpt.2012.10 10.1167/iovs.18-25466 10.1007/s40618-016-0484-y 10.1016/S2213-8587(16)30046-8 10.1016/j.sjopt.2017.09.003 10.1080/01676830.2018.1556704 10.18240/ijo.2018.08.18 10.1186/s40842-018-0073-4 10.1021/jm051197e 10.4103/meajo.MEAJO_91_17 10.1038/eye.2016.184 10.3389/fendo.2019.00192 10.3109/01676830903403174 10.5402/2012/739236 10.1016/j.sjopt.2012.07.006 10.1245/s10434-014-4095-6 10.1080/01676830590912562 10.3980/j..2222-3959.2014.02.31 10.1586/17469899.2014.917960 10.1055/a-0658-7889 10.1155/2018/4845894 10.1097/IOP.0000000000000077 10.1159/000494837 10.1210/jc.2014-1580 10.1016/S0140-6736(99)01465-8 10.1210/er.2013-1055 |
| ContentType | Journal Article |
| Copyright | 2020 Taylor & Francis Group, LLC 2020 |
| Copyright_xml | – notice: 2020 Taylor & Francis Group, LLC 2020 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1080/02713683.2020.1776331 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1460-2202 |
| EndPage | 1341 |
| ExternalDocumentID | 32567373 10_1080_02713683_2020_1776331 1776331 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 00X 03L 0R~ 29F 36B 4.4 5GY 5RE AAGDL AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLJU ABLKL ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ACIEZ ACNCT ACUHS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE AQTUD BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- P2P PQQKQ RNANH RVRKI SV3 TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UEQFS V1S ~1N AAYXX CITATION .55 .GJ 34G 39C 53G 5VS AALIY AAORF AAPXX ABWCV ABZEW ACKZS ACOPL ADFOM ADFZZ ADYSH AEIIZ AFFNX AFLEI AJVHN AWYRJ BRMBE CAG COF CYYVM CZDIS DRXRE DWTOO EJD JENTW M44 NPM NUSFT QQXMO RIG X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c483t-e88fccd99bcec7e0f715ca68eba443fac8a61602ff9987b376b486eb4f538a133 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 43 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000546481500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0271-3683 1460-2202 |
| IngestDate | Fri Sep 05 09:16:24 EDT 2025 Thu Apr 03 07:03:33 EDT 2025 Sat Nov 29 01:48:48 EST 2025 Tue Nov 18 21:11:33 EST 2025 Mon Oct 20 23:48:37 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | graves’ ophthalmopathy gene network analysis Thyroid-associated ophthalmopathy therapeutics decompression surgery & interventional medicine |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c483t-e88fccd99bcec7e0f715ca68eba443fac8a61602ff9987b376b486eb4f538a133 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-2856-4185 |
| OpenAccessLink | https://figshare.com/articles/journal_contribution/Clinical_Management_and_Therapeutic_Strategies_for_the_Thyroid-Associated_Ophthalmopathy_Current_and_Future_Perspectives/12850058 |
| PMID | 32567373 |
| PQID | 2415837454 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | informaworld_taylorfrancis_310_1080_02713683_2020_1776331 pubmed_primary_32567373 proquest_miscellaneous_2415837454 crossref_primary_10_1080_02713683_2020_1776331 crossref_citationtrail_10_1080_02713683_2020_1776331 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-01 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Current eye research |
| PublicationTitleAlternate | Curr Eye Res |
| PublicationYear | 2020 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | cit0033 cit0077 cit0034 cit0078 cit0031 cit0075 cit0032 cit0076 Kim SE (cit0029) 2012; 250 cit0073 cit0030 cit0074 cit0071 Hotta A (cit0038) 2018; 2018 cit0072 cit0070 cit0037 cit0035 cit0079 cit0036 cit0022 cit0066 cit0023 cit0067 cit0020 cit0064 cit0021 cit0065 cit0062 cit0063 cit0060 cit0061 cit0028 cit0026 cit0027 cit0024 Smith TJ (cit0039) 2017; 376 cit0068 cit0025 cit0069 cit0011 cit0055 cit0056 cit0053 cit0010 cit0054 cit0051 cit0095 cit0052 cit0093 cit0050 cit0094 cit0091 cit0092 cit0090 cit0019 Reddy SV (cit0012) 2014; 139 cit0017 cit0018 cit0015 cit0059 cit0016 cit0013 cit0057 cit0058 cit0044 cit0088 cit0001 cit0045 cit0089 cit0042 cit0086 cit0043 cit0087 cit0040 cit0084 cit0041 cit0085 cit0082 cit0083 cit0080 cit0081 cit0008 Rootman J (cit0014) 1998; 10 cit0009 cit0006 cit0007 cit0004 cit0048 cit0005 cit0049 cit0002 cit0046 cit0003 cit0047 |
| References_xml | – ident: cit0050 doi: 10.1016/j.ejro.2019.05.003 – ident: cit0044 doi: 10.2147/OPTH.S205112 – ident: cit0006 doi: 10.2174/1389201020666190725113816 – ident: cit0085 doi: 10.1097/IOP.0000000000000260 – ident: cit0095 doi: 10.1111/j.2517-6161.1995.tb02031.x – ident: cit0031 doi: 10.1167/iovs.13-12741 – ident: cit0089 doi: 10.1016/S1097-2765(04)00080-2 – ident: cit0028 doi: 10.1530/JOE-11-0162 – ident: cit0017 doi: 10.1007/s40618-018-0915-z – ident: cit0079 doi: 10.1016/j.beem.2019.101319 – ident: cit0065 doi: 10.1016/j.ajoc.2017.07.001 – ident: cit0040 doi: 10.1136/bjophthalmol-2014-305649 – ident: cit0042 doi: 10.2147/OPTH.S76583 – ident: cit0056 doi: 10.1038/s41598-017-17257-6 – ident: cit0033 doi: 10.1016/j.gene.2018.11.097 – ident: cit0049 doi: 10.1186/s12886-018-0969-x – ident: cit0002 doi: 10.1016/j.beem.2011.10.004 – ident: cit0054 doi: 10.2147/OPTH.S216838 – ident: cit0003 doi: 10.2169/internalmedicine.53.1518 – ident: cit0073 doi: 10.1038/sj.eye.6701768 – ident: cit0082 doi: 10.1007/s11684-017-0528-5 – ident: cit0094 doi: 10.1186/s12859-017-1559-2 – ident: cit0013 doi: 10.1097/ICU.0000000000000596 – ident: cit0036 doi: 10.1056/NEJMicm1506674 – ident: cit0035 doi: 10.1007/s40618-014-0097-2 – ident: cit0086 doi: 10.1038/s41433-018-0022-6 – ident: cit0060 doi: 10.1007/s40265-018-1045-9 – ident: cit0059 doi: 10.1259/bjr.20140677 – ident: cit0070 doi: 10.1056/NEJMoa1910434 – ident: cit0019 doi: 10.3389/fendo.2017.00137 – ident: cit0069 doi: 10.1056/NEJMoa1614949 – ident: cit0080 doi: 10.1038/s41598-017-17893-y – ident: cit0043 doi: 10.1146/annurev-pharmtox-010617-052509 – ident: cit0076 doi: 10.1055/a-0739-8134 – ident: cit0083 doi: 10.1016/j.survophthal.2017.03.007 – ident: cit0011 doi: 10.1089/thy.2008.0044 – ident: cit0090 doi: 10.1089/omi.2009.0045 – ident: cit0041 doi: 10.22088/cjim.9.2.178 – ident: cit0084 doi: 10.1016/j.jfma.2018.06.009 – ident: cit0004 doi: 10.1136/bjophthalmol-2015-307399 – ident: cit0037 doi: 10.1016/j.radcr.2019.04.021 – ident: cit0025 doi: 10.1038/s41433-018-0279-9 – ident: cit0001 doi: 10.12688/f1000research.12787.1 – ident: cit0057 doi: 10.1007/978-1-4939-7531-0_2 – ident: cit0047 doi: 10.1155/2015/249125 – ident: cit0007 doi: 10.1186/s40842-016-0037-5 – ident: cit0046 doi: 10.1136/bjo.73.8.639 – ident: cit0093 doi: 10.1093/nar/gky311 – ident: cit0088 doi: 10.1093/asj/sjy085 – ident: cit0067 doi: 10.1586/17512433.2016.1165606 – ident: cit0024 doi: 10.1038/s41433-018-0315-9 – ident: cit0030 doi: 10.1210/jcem.81.8.8768861 – ident: cit0058 doi: 10.1007/s00234-018-2103-4 – ident: cit0066 doi: 10.1080/14728222.2017.1288215 – ident: cit0026 doi: 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U – ident: cit0010 doi: 10.1016/S0002-9394(14)72666-2 – ident: cit0077 doi: 10.1016/j.jamcollsurg.2009.03.025 – ident: cit0053 doi: 10.15557/JoU.2015.0036 – ident: cit0008 doi: 10.1097/IOP.0000000000001446 – ident: cit0022 doi: 10.1167/iovs.14-14002 – ident: cit0048 doi: 10.1186/s12886-018-1018-5 – ident: cit0092 doi: 10.1038/srep42717 – ident: cit0005 doi: 10.1530/JME-17-0276 – ident: cit0027 doi: 10.1038/s41433-018-0265-2 – ident: cit0032 doi: 10.1038/clpt.2012.10 – ident: cit0034 doi: 10.1167/iovs.18-25466 – ident: cit0078 doi: 10.1007/s40618-016-0484-y – volume: 376 start-page: 185 year: 2017 ident: cit0039 publication-title: N Engl J Med doi: 10.1056/NEJMoa1614949 – ident: cit0071 doi: 10.1016/S2213-8587(16)30046-8 – volume: 250 start-page: 1521 year: 2012 ident: cit0029 publication-title: Clin Exp Immunol – volume: 2018 start-page: 1707959 year: 2018 ident: cit0038 publication-title: Case Rep Endocrinol – volume: 139 start-page: 99 year: 2014 ident: cit0012 publication-title: Indian J Med Res – ident: cit0081 doi: 10.1016/j.sjopt.2017.09.003 – ident: cit0052 doi: 10.1080/01676830.2018.1556704 – ident: cit0055 doi: 10.18240/ijo.2018.08.18 – volume: 10 start-page: 2 year: 1998 ident: cit0014 publication-title: Asia Pac J Ophthalmol – ident: cit0072 doi: 10.1186/s40842-018-0073-4 – ident: cit0091 doi: 10.1021/jm051197e – ident: cit0009 doi: 10.4103/meajo.MEAJO_91_17 – ident: cit0018 doi: 10.1038/eye.2016.184 – ident: cit0045 doi: 10.3389/fendo.2019.00192 – ident: cit0016 doi: 10.3109/01676830903403174 – ident: cit0087 doi: 10.5402/2012/739236 – ident: cit0051 doi: 10.1016/j.sjopt.2012.07.006 – ident: cit0020 doi: 10.1245/s10434-014-4095-6 – ident: cit0074 doi: 10.1080/01676830590912562 – ident: cit0063 doi: 10.3980/j..2222-3959.2014.02.31 – ident: cit0075 doi: 10.1586/17469899.2014.917960 – ident: cit0062 doi: 10.1055/a-0658-7889 – ident: cit0064 doi: 10.1155/2018/4845894 – ident: cit0015 doi: 10.1097/IOP.0000000000000077 – ident: cit0061 doi: 10.1159/000494837 – ident: cit0068 doi: 10.1210/jc.2014-1580 – ident: cit0021 doi: 10.1016/S0140-6736(99)01465-8 – ident: cit0023 doi: 10.1210/er.2013-1055 |
| SSID | ssj0002714 |
| Score | 2.4789255 |
| SecondaryResourceType | review_article |
| Snippet | TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1325 |
| SubjectTerms | decompression surgery & interventional medicine gene network analysis graves' ophthalmopathy therapeutics Thyroid-associated ophthalmopathy |
| Title | Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives |
| URI | https://www.tandfonline.com/doi/abs/10.1080/02713683.2020.1776331 https://www.ncbi.nlm.nih.gov/pubmed/32567373 https://www.proquest.com/docview/2415837454 |
| Volume | 45 |
| WOSCitedRecordID | wos000546481500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Journals customDbUrl: eissn: 1460-2202 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002714 issn: 0271-3683 databaseCode: TFW dateStart: 19810101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dT9swED-NakK8bKwdrONDRpp4y2hi13Z4QxMVLzAeita3yHFsgdSmqAmT-t_v7Djt-lDxAE9RPi6xnTvfnX33O4AfVCWsSKRbtYmHEZM8jlKlTISqi2sqGM-F9cUmxN2dnEzS-xBNWIWwSudD2wYows_VTrhVXrURcRfoScWUS4reXYKXBIqIz6RG1e9Eczz6s5qL8UkPIIXHyJG0OTzb3rKhnTawS7dboF4TjT6_Qx_24VMwQ8lVwzdf4IMpu9C7KtEFny3JOfGBoX7FvQu7t2H_vQfLACM6JeuwGYJtION1GhdpAW9NRbBjBC1MvL1czJ-KqGUGU5Dfz4_1o5rO5q4m8vKSBKAo_7aRBzoh9-tE0OorPIyux79uolC8IdJM0joyUlqtizTNtdHCDCzyglZcmlwxRq3SUvGYDxJr0eETOc5zOXKKyZnFKVih53wAnXJemm9ARGxSpqjkfFCwQZGnksbMSpYohcaMTvrA2p-W6YBs7gpsTLO4BUANo5250c7CaPfh54rsuYH2eI0g_Z8jstqvqdimAEpGX6E9a9knQwF2uzKqNPOXKnMmlESpGLI-HDZ8tWoORYNUUEG_v-HLR7DnTpv8yWPo1IsXcwIf9d_6qVqcwo6YyFMvNP8ADfMQOQ |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1RT9swED4hmBgvMGCDsgFGmvYW1sSu7ewNoVUgoNtDp_FmOY6tViopalOk_nvOTtLCA-IBniIlOcd27uy78913AN-pTlieSO-1iTsRkzyOUq1thFsXN1QwngkXik2IXk_e3qZPc2F8WKW3oV0FFBHWai_c3hndhMT9RFMqplxSNO8SvCVQRnwq9ZqvTufx8_vd_4vVGF8NEFJ4jTxNk8XzUjPP9qdn6KUv66BhL-puvccoPsFmrYmSs4p1tmHFFjuwe1agFX43Jz9IiA0NTvcdWL-pj-B3YV4jiY7IMnKGYCdIf5nJRRrMWzslODKCSiY-nk_Gwzxq-MHm5M_9oBzo0d3Yl0We_yI1VlRorRuwTsjfZS7o9DP86_7un19Edf2GyDBJy8hK6YzJ0zQz1gjbdsgORnNpM80YddpIzWPeTpxDm09kuNRlyCw2Yw5XYY3G8xdYLcaF3QciYpsyTSXn7Zy18yyVNGZOskRr1GdM0gLW_DVlanBzX2NjpOIGA7WebeVnW9Wz3YLTBdl9he7xGkH6lCVUGdwqrqqBougrtCcN_yiUYX8wows7nk2V16IkCkaHtWCvYqxFdyjqpIIKevCGLx_Dx4v-zbW6vuxdfYUN_6hKp_wGq-VkZg_hg3koh9PJUZCdR9jME3o |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED9NA028sLHx0bGBJyHeAk3s2g5vEywagpU-FLE3y3FsbVKXVk2G1P-es-O07GHaAzxFSnKO7dyd7-y73wG8ozpjVSb9rk06SpjkaZJrbRNcurihgvFSuFBsQozH8vIyn8RowiaGVXof2nVAEUFXe-FeVK6PiPuInlRKuaTo3WV4S6CI-EzqR2g6jzyTT4tfa2WMrwYEKbwmnqZP4rmvmTvL0x3w0vtN0LAUFbv_YRB78DTaoeS0Y5xnsGXrfTg4rdEHv1mR9yREhoYt933YuYgH8AewijiiM7KJmyHYBzLd5HGRHvHWNgQHRtDExMer5fy6SnpusBX5sbhqr_TsZu6LIq8-kYgUFVorAtIJmWwyQZvn8LM4m34-T2L1hsQwSdvESumMqfK8NNYIO3TIDEZzaUvNGHXaSM1TPsycQ49PlKjoSmQVWzKHOlij6_wCtut5bV8BEanNmaaS82HFhlWZS5oyJ1mmNVozJhsA63-aMhHa3FfYmKm0R0CNs638bKs42wP4sCZbdNgeDxHkf3OEasOmiusqoCj6AO1Jzz4KJdgfy-jazm8b5W0oiWIxYgN42fHVujsULVJBBT38hy-_hZ3Jl0J9_zr-9hqe-CddLuURbLfLW3sMj83v9rpZvgmS8weDThIs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Management+and+Therapeutic+Strategies+for+the+Thyroid-Associated+Ophthalmopathy%3A+Current+and+Future+Perspectives&rft.jtitle=Current+eye+research&rft.au=Mishra%2C+Shailja&rft.au=Maurya%2C+Vimal+K&rft.au=Kumar%2C+Swatantra&rft.au=Ankita&rft.date=2020-11-01&rft.eissn=1460-2202&rft.volume=45&rft.issue=11&rft.spage=1325&rft_id=info:doi/10.1080%2F02713683.2020.1776331&rft_id=info%3Apmid%2F32567373&rft.externalDocID=32567373 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-3683&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-3683&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-3683&client=summon |